Zhejiang Cheng Yi Pharmaceutical Co., Ltd. Class A(603811 CG)
$6.63+0.071.07%(Market Closed · 07:00:02 UTC · (15 min delay))
- Pricing and plans
Get the full experience
We save the real magic for signed-in users.
Get the full experience
We save the real magic for signed-in users.
| Millions CNY (ex. Per Share) | FY201112/31/2011 | FY201212/31/2012 | FY201312/31/2013 | FY201412/31/2014 | FY201512/31/2015 | FY201612/31/2016 | FY201712/31/2017 | FY201812/31/2018 | FY201912/31/2019 | FY202012/31/2020 | FY202112/31/2021 | FY202212/31/2022 | FY202312/31/2023 | FY202412/31/2024 | FY202512/31/2025 | Last 12M06/30/2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 671.6 | 714.4 | 812.3 | 827.5 | ||||||||||||||
| -Cost of Revenue | 248.5 | 225.2 | 245.3 | 254.6 | ||||||||||||||
| Gross Profit | 423.2 | 489.2 | 567.0 | 572.9 | ||||||||||||||
| -Operating Expenses | 249.3 | 268.0 | 342.4 | 374.6 | ||||||||||||||
| +Selling, General & Admin | 246.5 | 308.1 | 194.5 | 205.1 | ||||||||||||||
| +General And Administrative Expenses | 94.3 | 126.1 | 27.7 | 7.0 | ||||||||||||||
| +Selling And Marketing Expenses | 152.1 | 182.0 | 166.8 | 120.9 | ||||||||||||||
| +Research and Development | 47.1 | 47.1 | 44.4 | 47.7 | ||||||||||||||
| +Other Operating Expenses | -44.4 | -87.2 | 103.5 | 121.9 | ||||||||||||||
| Operating Income | 173.9 | 221.2 | 224.6 | 198.2 | ||||||||||||||
| +Non Operating Income | -6.2 | -11.2 | -4.4 | 6.7 | ||||||||||||||
| +Interest Income, Net | -6.3 | -8.1 | -3.6 | -1.2 | ||||||||||||||
| +Interest Income | 9.0 | 3.0 | 0.2 | 0.4 | ||||||||||||||
| -Interest Expense | 15.3 | 11.2 | 3.8 | 1.6 | ||||||||||||||
| +Other Non-Op Income | 0.2 | -3.1 | -0.8 | 7.9 | ||||||||||||||
| Pretax Income | 174.1 | 218.1 | 223.8 | 206.1 | ||||||||||||||
| -Income Tax Expense | 12.0 | 17.3 | 26.4 | 26.8 | ||||||||||||||
| Income from Cont Ops | 162.0 | 200.8 | 197.5 | 179.3 | ||||||||||||||
| -Net Extraordinary Losses | - | - | - | - | ||||||||||||||
| +Discounted operations | - | - | - | - | ||||||||||||||
| +XO & Accounting Changes | - | - | - | - | ||||||||||||||
| Income Incl. MI | 162.0 | 200.8 | 197.5 | 179.3 | ||||||||||||||
| -Minority Interests | -0.8 | 0.1 | 2.3 | 1.7 | ||||||||||||||
| Net Income, GAAP | 162.9 | 200.7 | 195.1 | 177.6 | ||||||||||||||
| -Prfrrd Div & Other | - | - | - | - | ||||||||||||||
| Net Income Avail To Common | 162.9 | 200.7 | 195.1 | 177.6 | ||||||||||||||
| Weighted Average Shs Out | 325,793,316.0 | 329,017,668.0 | 319,863,470.0 | 1,388,296,787.0 | ||||||||||||||
| EPS | 0.5 | 0.6 | 0.6 | 0.5 | ||||||||||||||
| Weighted Average Shs Out Dil | 325,793,316.0 | 329,017,668.0 | 319,863,470.0 | 1,388,293,952.0 | ||||||||||||||
| EPS Diluted | 0.5 | 0.6 | 0.6 | 0.5 | ||||||||||||||